Abstract
Eli Lilly & Co. is mulling the future of its Elanco animal health unit, which is on track to have sales this year of roughly $3 billion. Stock analysts think the unit, which could be spun off, sold, or kept by Lilly, is worth between $12 billion and $15 billion. Lilly will decide the unit’s fate by mid-2018. The animal health business played a critical role in buttressing Lilly’s bottom line during a rocky few years of patent losses on many of its best-selling pharmaceutical products. But the unit has recently faced challenges at a time when the human health business is improving. In the third quarter, new medicines accounted for nearly all Lilly’s revenue growth. In a call with analysts to discuss Lilly’s third-quarter earnings, Lilly’s CEO, David Ricks, acknowledged that investors have for years questioned whether the animal health unit should stand alone. He said the timing is
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.